Lisanti Capital Growth LLC Takes Position in Teleflex Incorporated (TFX)

Lisanti Capital Growth LLC acquired a new position in Teleflex Incorporated (NYSE:TFX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,645 shares of the medical technology company’s stock, valued at approximately $438,000.

Other institutional investors have also recently modified their holdings of the company. Parallel Advisors LLC lifted its stake in shares of Teleflex by 200.0% in the second quarter. Parallel Advisors LLC now owns 450 shares of the medical technology company’s stock worth $120,000 after buying an additional 300 shares during the last quarter. First Hawaiian Bank acquired a new stake in shares of Teleflex in the third quarter worth $156,000. Qube Research & Technologies Ltd acquired a new stake in shares of Teleflex in the second quarter worth $168,000. First Light Asset Management LLC acquired a new stake in shares of Teleflex in the second quarter worth $210,000. Finally, Dupont Capital Management Corp lifted its stake in shares of Teleflex by 80.5% in the second quarter. Dupont Capital Management Corp now owns 832 shares of the medical technology company’s stock worth $223,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 89.36% of the company’s stock.

Several equities analysts recently commented on the stock. Needham & Company LLC cut their target price on shares of Teleflex from $298.00 to $279.00 and set a “buy” rating for the company in a research note on Friday, August 3rd. ValuEngine cut shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, August 3rd. Piper Jaffray Companies upped their target price on shares of Teleflex to $310.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. TheStreet cut shares of Teleflex from a “b” rating to a “c+” rating in a research note on Friday, August 3rd. Finally, Barclays assumed coverage on shares of Teleflex in a research note on Monday, October 15th. They set an “equal weight” rating and a $266.00 target price for the company. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Teleflex presently has an average rating of “Buy” and a consensus price target of $289.38.

NYSE:TFX opened at $265.88 on Friday. The firm has a market cap of $12.11 billion, a P/E ratio of 27.49, a P/E/G ratio of 2.13 and a beta of 1.12. Teleflex Incorporated has a one year low of $227.52 and a one year high of $288.78. The company has a quick ratio of 1.51, a current ratio of 2.26 and a debt-to-equity ratio of 0.83.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 1st. The medical technology company reported $2.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.11. The firm had revenue of $609.70 million during the quarter, compared to analysts’ expectations of $609.05 million. Teleflex had a net margin of 2.81% and a return on equity of 18.04%. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.12 EPS. As a group, analysts forecast that Teleflex Incorporated will post 9.91 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Thursday, November 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Wednesday, November 14th. Teleflex’s payout ratio is currently 16.19%.

In other Teleflex news, CFO Thomas E. Powell sold 5,200 shares of the business’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $240.02, for a total value of $1,248,104.00. Following the sale, the chief financial officer now owns 15,351 shares of the company’s stock, valued at approximately $3,684,547.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Benson Smith sold 9,331 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $247.69, for a total transaction of $2,311,195.39. Following the completion of the sale, the director now directly owns 77,887 shares in the company, valued at approximately $19,291,831.03. The disclosure for this sale can be found here. Insiders sold a total of 91,660 shares of company stock worth $23,423,228 in the last three months. Insiders own 2.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Lisanti Capital Growth LLC Takes Position in Teleflex Incorporated (TFX)” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/11/10/lisanti-capital-growth-llc-takes-position-in-teleflex-incorporated-tfx.html.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Read More: Understanding the different types of bonds

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply